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1. PUBLIC HEALTH STATEMENT
 
This Statement was prepared to give you information about
 
1,2-diphenylhydrazine and to emphasize the human health effects that may
 
result from exposure to it. The Environmental Protection Agency (EPA) has
 
identified 1177 sites on its National Priorities List (NPL). 1,2­
Diphenylhydrazine has been found at 7 of these sites. However, we do not know
 
how many of 1177 NPL sites have been evaluated for 1,2-diphenylhydrazine. As
 
EPA evaluates more sites, the number of sites at which 1,2-diphenylhydrazine
 
is found may change. The information is important for you because 1,2­
diphenylhydrazine may cause harmful health effects and because these sites are
 
potential are actual sources of human exposure to 1,2-diphenylhydrazine.
 
When a chemical is released from a large area, such as an industrial
 
plant, or from a container, such as a drum or bottle, it enters the
 
environment as a chemical emission. This emission, which is also called a
 
release, does not always lead to exposure. You can be exposed to a chemical
 
only when you come into contact with the chemical. You may be exposed to it in
 
the environment by breathing, eating, or drinking substances containing the
 
chemical or from skin contact with it.
 
If you are exposed to a hazardous substance such as 1,2­
diphenylhydrazine, several factors will determine whether harmful health
 
effects will occur and what the type and severity of those health effects will
 
be. These factors include the dose (how much), the duration (how long), the
 
route or pathway by which you are exposed (breathing, eating, drinking, or
 
skin contact), the other chemicals to which you are exposed, and your
 
individual characteristics such as age, sex, nutritional status, family
 
traits, life style, and state of health.
 
1.1 WHAT IS 1,2-DIPHENYLHYDRAZINE?
 
1,2-Diphenylhydrazine is a white solid. It dissolves only slightly in
 
water and does not change into a gas unless it is heated to very high
 
temperatures. It sticks to soil and can be carried into the air along with
 
windblown dust. Once in water or exposed to air it is changed into other
 
chemicals within minutes. These chemicals include the toxic chemicals
 
azobenzene and benzidine. More information about these two chemicals can be
 
found in the ATSDR Toxicological Profile on Benzidine or by contacting the
 
Agency for Toxic Substances and Disease Registry (see Section 1.8).
 
1,2-diphenylhydrazine is used to make fabric dyes in other countries,
 
and to make certain medicines. There are no other major manmade or natural
 
sources of 1,2-diphenylhydrazine. More information on these subjects can be
 
found in Chapters 3, 4, and 5.
 
1.2 HOW MIGHT I BE EXPOSED TO 1,2-DIPHEXYLHYDRAZINE?
 
1,2-Diphenylhydrazine does not dissolve in water easily and reacts
 




1. PUBLIC HEALTH STATEMENT
 
would be exposed to it by drinking water. Also, 1,2-diphenylhydrazine does not
 
change to a gas at normal outside temperatures. Therefore, it is extremely
 
unlikely that you would be exposed to it by breathing air even if you live
 
near a hazardous waste site. Because 1,2-diphenylhydrazine may stick to soil,
 
it is possible that you could breathe in dust coated with 1,2­
diphenylhydrazine if you entered a hazardous waste site in which it had been
 
recently spilled on the ground. It is also possible that children playing at
 
this hazardous waste site could be exposed by eating dirt or smearing dirt on
 
their skin. It would have to be a site in which the 1,2-diphenylhydrazine was
 
recently spilled on the ground, since once exposed to air, 1,2­
diphenylhydrazine changes into other substances within minutes.
 
You also could be exposed to 1,2-diphenylhydrazine if you work in an
 
industry in which it is used. For example, while working, you could be
 
exposed to dust containing 1,2-diphenylhydrazine when it is moved from one
 
place to another. It has not been found in food or in air or natural soils.
 
If 1,2-diphenylhydrazine exists at all in lakes or streams, it is probably at
 
levels that are less than 1 part 1,2-diphenylhydrazine in l,OOO,OOO parts
 
water (ppm). More information on how you could be exposed to 1,2­
diphenylhydrazine can be found in Chapter 5.
 
1.3 HOW CAN 1,2-DIPHENYLHYDRAZINE ENTER AND LEAVE MY BODY?
 
If you were to breathe in dust coated with 1,2-diphenylhydrazine you
 
would probably breathe out most of it within a few minutes; however, some of
 
it might enter your body. Also, if you were to eat dust or dirt coated with
 
1,2-diphenylhydrazine, some of it might enter your body. However, we do not
 
know how much or how long it would take for the 1,2-diphenylhydrazine that you
 
breathe in or eat to enter your body. It is not known if 1,2-diphenylhydrazine
 
would enter your body if you were to spill it on your skin or if your were to
 
get dirt coated with it on your skin. Some, maybe most of 1,2­
diphenylhydrazine that enters your body leaves your body in the urine. It is
 
not known how long it takes for 1,2-diphenylhydrazine to leave the body in the
 
urine. Additional information on how 1,2-diphenylhydrazine can enter and leave
 
your body is presented in Chapter 2.
 
1.4 HOW CAN 1,2-DIPHENYLHYDRAZINE AFFECT MY HEALTH?
 
It is not known if 1,2-diphenylhydrazine would affect your health if you
 
were to breathe it in or eat it. The health effects of 1,2-diphenylhydrazine
 
in humans have not been studied. Animals die if they swallow large amounts of
 
1,2-diphenylhydrazine, and develop liver disease if they eat small amounts of
 
1,2-diphenylhydrazine for more than a year. Therefore, it is possible that if
 
you were to eat large amounts of 1,2-diphenylhydrazine for a long time you
 
might experience liver damage or die. It is not known whether 1,2­
diphenylhydrazine would harm you if you were to spill it on your skin. It is
 
not known if 1,2-diphenylhydrazine causes birth defects or affects fertility.
 
It is not known if 1,2-diphenylhydrazine causes cancer in humans; however, it
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lifetime. Additional information on the health effects of 1,2­
diphenylhydrazine is presented in Chapter 2.
 
1.5 WHAT LEVELS OF EXPOSURE HAVE RESULTED IN HARMFUL HEALTH EFFECTS?
 
Tables l-l, l-2, l-3, and l-4 show how little we know about the levels
 
of 1,2-diphenylhydrazine that might affect your health. As is shown in Table
 
l-4, animals that ate food containing 1,2-diphenylhydrazine for a long time
 
developed lung inflammation, stomach damage, and liver damage, and some died.
 
Although the levels of exposure that cause harmful effects in humans are not
 
known, as discussed in Section 1.2, 1,2-diphenylhydrazine is not likely to be
 
found in food, and you are not even likely to be exposed to levels of concern
 
if you live near a hazardous waste site. Additional information on levels of
 
exposure associated with effects can be found in Chapter 2.
 
1.6 IS THERE A MEDICAL TEST TO DETERMINE WHETHER I HAVE BEEN EXPOSED TO 1,2­
DIPHENYIHYDRAZINE?
 
There is no test to determine if you have been exposed to
 
1,2-diphenylhydrazine. More information about tests for exposure and
 
effects can be found in Chapters 2 and 6.
 




A guideline to protect human health, by limiting exposure to
 
1,2-diphenylhydrazine in water, has been issued by the federal government.
 
The U.S. Environmental Protection Agency (EPA) has made recommendations to
 
limit the concentration of 1,2-diphenylhydrazine in natural waters, such as
 
lakes and streams. The EPA has developed regulations to limit the release
 
of 1,2-diphenylhydrazine by industries. Any release of 1 pound or more of
 
1,2-diphenylhydrazine must be reported to EPA.
 
1.8 WHERE CAN I GET MORE INFORMATION?
 
If you have any more questions or concerns not covered here, please
 
contact your State Health or Environmental Department or:
 








This agency can also give you information on the location of the
 
nearest occupational and environmental health clinics. Such clinics
 
specialize in the recognizing, evaluating, and treating illnesses that
 













This chapter contains descriptions and evaluations of studies and
 
interpretation of data on the health effects associated with exposure to
 
1,2-diphenylhydrazine. Its purpose is to present levels of significant
 
exposure for 1,2-diphenylhydrazine based on toxicological studies,
 
epidemiological investigations, and environmental exposure data. This
 
information is presented to provide public health officials, physicians,
 
toxicologists, and other interested individuals and groups with (1) an
 
overall perspective of the toxicology of 1,2-diphenylhydrazine and (2) a
 




2.2 DISCUSSION OF HEALTH EFFECTS BY ROUTE OF EXPOSURE
 
To help public health professionals address the needs of persons
 
living or working near hazardous waste sites, the data in this section are
 
organized first by route of exposure -- inhalation, oral, and dermal -- ant
 
then by health effect -- death, systemic, immunological, neurological,
 
developmental, reproductive, genotoxic, and carcinogenic effects. These
 




Levels of significant exposure for each exposure route and duration
 
(for which data exist) are presented in tables and illustrated in figures.
 
The points in the figures showing no-observed-adverse-effect levels (NOAELs)
 
or lowest-observed-adverse-effect levels (LOAELs) reflect the actual doses
 
(levels of exposure) used in the studies. LOAELs have been classified into
 
"less serious" or "serious" effects. These distinctions are intended to
 
help the users of the document identify the levels of exposure at which
 
adverse health effects start to appear, determine whether or not the
 
intensity of the effects varies with dose and/or duration, and place into
 
perspective the possible significance of these effects to human health.
 
The significance of the exposure levels shown on the tables and graphs
 
may differ depending on the user's perspective. For example, physicians
 
concerned with the interpretation of clinical findings in exposed persons or
 
with the identification of persons with the potential to develop such
 
disease may be interested in levels of exposure associated with "serious"
 
effects. Public health officials and project managers concerned with
 
response actions at Superfund sites may want information on levels of
 
exposure associated with more subtle effects in humans or animals (LOAEL) or
 
exposure levels below which no adverse effects (NOAEL) have been observed.
 
Estimates of levels posing minimal risk to humans (minimal risk levels,
 
MRLs) are of interest to health professionals and citizens alike.
 
For certain chemicals, levels of exposure associated with carcinogenic
 
effects may be indicated in the figures. These levels reflect the actual
 






Because cancer effects could occur at lower exposure levels, the figures
 
also show estimated excess risks, ranging from a risk of one in 10,000 to one
 
in 10,000,000 (10-4 to 10-7), as developed by EPA.
 
Estimates of exposure levels posing minimal risk to humans (MRLs) have
 
been made, where data were believed reliable, for the most sensitive
 
noncancer end point for each exposure duration. MRLs include adjustments to
 
reflect human variability and, where appropriate, the uncertainty of
 
extrapolating from laboratory animal data to humans. Although methods have
 
been established to derive these levels (Barnes et al. 1987; EPA 1989),
 
uncertainties are associated with the techniques. Furthermore, ATSDR
 
acknowledges additional uncertainties inherent in the application of these
 
procedures to derive less than lifetime MRLs. As an example, acute
 
inhalation MRLs may not be protective for health effects that are delayed in
 
development or are acquired following repeated acute insults, such as
 
hypersensitivity reactions, asthma, or chronic bronchitis. As these kinds
 
of health effects data become available and methods to assess levels of
 




No studies were located regarding the following health effects in
 






















No studies were located regarding lethality in humans following oral
 
exposure to 1,2-diphenylhydrazine. Limited information is available
 
regarding the lethality of orally-administered 1,2-diphenylhydrazine in
 
animals. This consists of an incompletely documented acute LD50 of
 






1213 mg/kg/day in mice (Schafer and Bowles 1985), lethal doses for
 
intermediate duration exposure (4 weeks) of 54 mg/kg/day in rats and 390
 
mg/kg/day in mice (NTP 1983), and nonlethal and lethal doses for chronic
 
exposure in rats (2 and 5 mg/kg/day, respectively) and mice (10 and 52
 
mg/kg/day, respectively) (NTP 1983). The animal lethality data are
 
discussed below and summarized in Table 2-l.
 
A single-dose LD50 of 959 mg/kg was determined for rats treated by 
gavage with 1,2-diphenylhydrazine in water suspension (Marhold et al. 1968). 
Apparently, this value was determined using conventional methodology but the 
duration of observation was not reported and it was not indicated if 
treatment with undegraded compound was assured. Degradation could be an 
issue because 1,2-diphenylhydrazine degrades rapidly in water (Chapter 5). 
The cause(s) of mortality in the rats was not reported. The 959 mg/kg LD50 
is recorded in Table 2-l and plotted in Figure 2-l.
 In another study, the average amount of 1,2-diphenylhydrazine consumed
 
by wild deer mice over a 3-day period without killing more than 50% of the
 
mice was determined to be 1213 mg/kg/day (Schafer and Bowles 1985). The
 
validity of this finding is uncertain; however, as the dose was estimated from
 
consumption of seeds treated with only one concentration of chemical, only
 
five mice were treated, and the actual number of deaths was not reported.
 
Because of these limitations, the 1213 "g/kg/day dose is not a
 
reliable effect level for lethality due to acute duration exposure.
 
Small groups (five) of rats or mice of each sex were administered
 
various concentrations of 1,2-diphenylhydrazine in the diet for 4 weeks,
 
followed by 2 weeks without treatment (NCI 1978). Estimated doses ranged
 
from 3.5-210 mg/kg/day (eight dose levels) in male rats and 0.04-2600
 
mg/kg/day (nine dose levels) in female rats. Deaths occurred in 2 of 5 male
 
rats at 54 mg/kg/day and in all rats of both sexes at higher doses,
 
Although small numbers of rats were tested at each dose, it can be assumed
 
that the mortality at 54 mg/kg/day was related to treatment because of death
 
at higher doses. The 54 mg/kg/day dose, therefore, is a LOAEL value for
 
lethality in rats due to intermediate duration exposure (Table 2-1, Figure
 
2-l). In mice, estimated doses ranged from 9.1-550 mg/kg/day (eight dose
 
levels) in males and 0.39-6700 mg/kg/day (nine dose levels) in females.
 
Deaths occurred in 1 of 5 male mice at 390 mg/kg/day, 2 of 5 male mice at
 
550 mg/kg/day, 4 of 5 male mice at 950 mg/kg/day, and in all female mice at
 
6700 mg/kg/day. Using the reasoning used for the rat LOAEL, the 390
 
mg/kg/day dose can be considered a LOAEL for lethality in mice for
 
intermediate duration of exposure (Table 2-1, Figure 2-l). Because of
 
uncertainty related to the small size of the groups, the doses below the rat
 
and mouse LOAELs are not reliable NOAELs for lethality. The cause(s) of the
 
mortality in these studies was not indicated.
 
Rats and mice were fed diets that contained 1,2-diphenylhydrazine for
 
78 weeks, followed by 28-30 weeks (rats) or 17-18 weeks (mice) without
 









in males, and 2 and 5 mg/kg/day in females. Mortality was increased
 
significantly only in the high-dose female rats, indicating that 5 mg/kg/day
 
is a LOAEL for decreased survival due to chronic exposure (Table 2-1, Figure
 
2-l). These data suggest that female rats are more sensitive than male
 
rats. Because females appear to be the more sensitive sex and it is not
 
known if 4 mg/kg/day (the NOAEL in males that is below the 5 mg/kg/day LOAEL
 
in females) is lethal in females, the 2 mg/kg/day dose in females is the
 
most reliable NOAEL for lethality in this species. Estimated doses for the
 
mice were 10 and 52 mg/kg/day in males and 5.2 and 52 mg/kg/day in females.
 
Mortality was increased significantly in both the high-dose male and female
 
mice, indicating that the 52 mg/kg/day dose is the LOAEL and 10 mg/kg/day is
 
the highest NOAEL for lethality in mice due to chronic exposure (Table 2-1,
 






No studies were located regarding cardiovascular, hematological
 
musculoskeletal, renal, or dermal/ocular systemic effects in humans or
 
animals following oral exposure to 1,2-diphenylhydrazine.
 
Respiratory Effects. No studies were located regarding respiratory
 
effects of 1,2-diphenylhydrazine in humans. One animal study, discussed
 
below, indicates that chronic oral administration of 1,2-diphenylhydrazine
 
produced interstitial inflammation of the lungs in rats (NCI 1978).
 
Evaluation of the incidence data for nonneoplastic lesions in the NCI
 
(1978) chronic oral study shows that there were statistically increased
 
incidences of interstitial inflammation in the lungs of male rats. These
 
rats were treated with 1,2-diphenylhydrazine in the diet at doses of 4 or
 
mg/kg/day for 78 weeks. Increased incidences of this lesion were also
 
observed in female rats treated similarly with a dose of 2 mg/kg/day, but
 
not in mice treated similarly with doses of 5.2 mg/kg/day (females), 10
 
w/k/day (males), or 52 mg/kg/day (males and females). The highest NOAEL
 
value in mice and the LOAEL in rats for respiratory effects due to chronic
 
exposure are recorded in Table 2-1 and plotted in Figure 2-1.
 
Gastrointestinal Effects. No studies were located regarding
 
gastrointestinal effects of 1,2-diphenylhydrazine in humans. As discussed
 
below, gastrointestinal effects were observed in an intermediate duration
 
study with mice (intestinal hemorrhage) (NCI 1978) and a chronic study with
 
rats (stomach hyperkeratosis and acanthosis) (NCI 1978).
 
NCI (1978) concluded from pathological examinations of mice that died
 
in a 4-week diet study of 1,2-diphenylhydrazine that, "Intestinal hemorrhage
 
was the single gross abnormality consistently observed in these mice." The
 
severity of the hemorrhage was not described. As indicated in Section
 
2.2.2.1, deaths occurred in mice at doses 390 mg/kg/day or more but not 280
 






died from similar treatment with doses as high as 2600 mg/kg/day. Based on
 
these data, the 390 mg/kg/day dose can be considered a LOAEL for
 
gastrointestinal effects in mice due to intermediate duration exposure
 
(Table 2-1, Figure 2-l). As histological examinations were not conducted on
 
any of the animals, reliable NOAELs for gastrointestinal effects due to
 
intermediate exposure in either species cannot be identified.
 
Evaluation of the incidence data for nonneoplastic lesions in the NCI
 
(1978) chronic oral study shows that there were statistically increased
 
incidences of stomach hyperkeratosis and acanthosis in the high dose male
 
rats. These rats were treated with 1,2-diphenylhydrazine in the diet at a
 
dose of 15 mg/kg/day for 78 weeks. Increased incidences of these lesions
 
were not observed in male rats treated with 4 mg/kg/day, female rats
 
treated similarly with doses of 2 or 5 mg/kg/day, or mice treated similarly
 
with doses of 5.2 mg/kg/day (females), 10 mg/kg/day (males), or 52
 
mg/kg/day (males or females). Due to the prevalence of the hyperkeratosis
 
(21% versus 4% in controls) and acanthosis (36% versus 4% in controls),
 
appearance of these lesions due to dietary treatment (they are more commonly
 
associated with gavage treatment), and occurrence of gross intestinal
 
hemorrhage in mice treated with higher doses of 1,2-diphenylhydrazine in the
 
4-week NCI (1978) study, the effects are considered to be adverse. The 15
 
mg/kg/day dose therefore is a LOAEL for gastrointestinal effects in rats
 
due to chronic duration exposure (Table 2-1, Figure 2-l). The highest doses
 
not producing gastrointestinal histologic alterations in the rats (5
 
mg/kg/day) and mice (52 mg/kg/day) are NOAELs for gastrointestinal effects
 
due to chronic exposure (Table 2-1, Figure 2-l).
 
Hepatic Effects. No studies were located regarding hepatic effects of
 
1,2-diphenylhydrazine in humans. Chronic oral administration of
 
1,2-diphenylhydrazine produced degenerative alterations in the liver of rats
 
(fatty metamorphosis) and mice (coagulative necrosis) (NCI 1978).
 
Evaluation of the incidence data for nonneoplastic lesions in the NCI
 
(1978) chronic oral study shows that there was a statistically increased
 
incidence of fatty metamorphosis of the liver in the high-dose male rats
 
(20% versus 0% in controls). These rats were treated with
 
1,2-diphenylhydrazine in the diet at a dose of 15 mg/kg/day for 78 weeks.
 
Fatty metamorphosis was also observed in 20% of the high dose (5 mg/kg/day)
 
female rats. Although the increased incidence in the high dose female rats
 
was not statistically significant when compared with the incidence (12%) in
 
the matched control group, the incidence was statistically significant when
 
compared with the incidence (4%) in the control group for the low dose group
 
of females. Female mice treated similarly with 52 mg/kg/day had a
 
statistically increased incidence of coagulative necrosis of the liver (13%
 
versus 0% in controls). High incidences of focal necrosis were seen in low
 
dose female rats, the high dose control male and female mice, the low dose
 
treated male and female mice, and the high dose treated male mice. The
 
incidence in the low dose female rats was significantly increased above the
 






treated group. A similar effect was not seen in the high dose female rats.
 
The high incidence of focal necrosis in the high dose control groups makes
 
meaningful interpretation of the toxicological significance of this
 
particular lesion difficult. Nevertheless, because of the severity and
 
prevalence of the liver lesions taken together and the fact that hepatic
 
neoplasms were observed in this study, the liver is a major target organ of
 
1,2-diphenylhydrazine in both species. The highest NOAEL value and all
 
reliable LOAEL values for hepatic effects in both species for chronic
 
exposure are recorded in Table 2-l and plotted in Figure 2-l.
 
Other Systemic Effects. No studies were located regarding other
 
systemic effects of 1,2-diphenylhydrazine in humans. Decreased body weight
 
gain and/or weight loss was observed in chronic oral studies with rats and
 
mice (NCI 1978). As discussed below, these effects may be a consequence of
 
other toxic effects or cancer.
 
Initial and final body weights were not significantly different in rats
 
treated with 19 mg/kg/day in the diet for 288 days (Marhold et al. 1968).
 
Other endpoints of systemic toxicity were not reported in this study. Body
 
weights were not depressed consistently in rats and mice treated with
 
1,2-diphenylhydrazine in the diet at doses as high as 2600 mg/kg/day (rats)
 
or 6700 mg/kg/day (mice) for 4 weeks, followed by 2 weeks without treatment
 
(NCI 1978). These NOAELs for rats and mice are presented in Table 2-l and
 
Figure 2-l as other systemic effects for intermediate duration exposure.
 
Male rats treated with 1,2-diphenylhydrazine in the diet at a dose of
 
15 mg/kg/day for 78 weeks had approximately l0-15% decreased body weight
 
gain (NCI 1978). NCI/NTP usually considers effects on body weight of this
 
magnitude to be significant. Treatment-related effects on body weight were
 
not apparent in male or female rats treated similarly with doses of 2-5
 
mg/kg/day . With the exception of respiratory, gastrointestinal, and hepatic
 
alterations at 15 mg/kg/day (discussed previously), comprehensive
 
histological examinations of the rats did not show treatment-related
 
nonneoplastic lesions. Although food consumption data were not reported,
 
the decreased weight gain is probably secondary to toxic or neoplastic
 
effects and should be considered an adverse effect. The doses of 15
 
mg/kg/day and 5 mg/kg/day therefore are the LOAEL and highest NOAEL,
 
respectively, for other systemic effects in rats due to chronic duration
 
exposure (Table 2-1, Figure 2-l).
 
Male and female mice treated with 1,2-diphenylhydrazine in the diet at
 
a dose of 52 mg/kg/day for-78 weeks had decreased weight gain and subsequent
 
weight loss (approximately 30% at termination of the study) (NCI 1978).
 
Treatment-related effects on body weight were not apparent in mice treated
 
similarly with 5.2 mg/kg/day (females) or 10 mg/kg/day (males). Except for
 
hepatic alterations at 52 mg/kg/day (discussed previously), comprehensive
 
histological examinations of the mice showed no treatment-related
 
nonneoplastic lesions. As body weight loss is an adverse effect, the
 






chronic duration exposure (Table 2-1, Figure 2-l). The highest NOAEL for
 




No studies were located regarding immunological effects in humans or
 




No studies were located regarding neurological effects in humans after
 
oral exposure to 1,2-diphenylhydrazine.
 
Clinical signs and histological examinations of the brain were
 
unremarkable in rats and mice treated with 1,2-diphenylhydrazine in the diet
 
at doses of 15 and 52 mg/kg/day, respectively, for 78 weeks (NCI 1978).
 
These data provide an inadequate basis for evaluating possible
 




No studies were located regarding developmental effects in humans or
 




No studies were located regarding reproductive effects in humans after
 
oral exposure to 1,2-diphenylhydrazine.
 
Histological examinations of the seminal vesicle, testes, prostate,
 
uterus, ovaries, and mammary gland were unremarkable in rats and mice
 
treated with 1,2-diphenylhydrazine in the diet at doses as high as 15 and 52
 
mg/kg/day, respectively, for 78 weeks (NCI 1978). These data provide an
 
insufficient basis for evaluating reproductive toxicity, as reproductive
 




No studies were located regarding genotoxic effects in humans after
 
oral exposure to 1,2-diphenylhydrazine.
 
Sex-linked recessive lethal mutations were not produced in Drosophila
 
fed ethanol solution containing 50 ppm 1,2-diphenylhydrazine for 3 days
 
(Yoon et al. 1985). No oral genotoxicity studies of 1,2-diphenylhydrazine
 








No studies were located regarding carcinogenic effects in humans after
 
oral exposure to 1,2-diphenylhydrazine. As discussed below, chronic oral
 




Treatment-related neoplasms occurred in rats and mice that were
 
treated with low or high doses of 1,2-diphenylhydrazine in the diet for 78
 
weeks, followed by untreated observation periods of 28 or 30 weeks (rats)
 
and 17 or 18 weeks (mice) (NC1 1978). Male rats had statistically
 
significant increased incidences of hepatocellular carcinomas or neoplastic
 
nodules in the liver due to treatment with 4 mg/kg/day and 15 mg/kg/day, and
 
squamous-cell carcinomas of the Zymbal's gland and adrenal pheochromocytomas
 
resulted from treatment with 15 mg/kg/day. Incidences of liver neoplastic
 
nodules and mammary gland adenocarcinomas were increased significantly in
 
female rats treated with 5 mg/kg/day, but not 2 mg/kg/day. A significantly
 
increased incidence of hepatocellular carcinoma occurred in female mice
 
treated with 52 mg/kg/day, but not 5.2 mg/kg/day. Doses of 10.4 or 52
 
mg/kg/day were not neoplastic for male mice.
 
Tumors were not observed in male rats treated with 19 mg/kg/day doses
 
of 1,2-diphenylhydrazine in the diet for life (mean survival time =
 
288 days) (Marhold et al. 1968). The significance of this finding is
 
uncertain because the type and scope of pathological examination were not
 
reported. Pliss (1974) reported increased numbers of tumors of the liver,
 
Zymbal's gland, mammary gland and other sites in rats that were treated wit
 
1,2-diphenylhydrazine in the diet at an estimated dose of 85 mg/kg/day, 5
 
days/week for 588 days (Pliss 1974). These findings are inconclusive,
 
however, because of lack of control data and other report inadequacies.
 
The lowest Cancer-Effect-Levels (CELs) in the NCI (1978) bioassay are 
the doses that caused hepatocellular carcinoma in rats (4 mg/kg/day) and 
mice (52 mg/kg/day) (Table 2-1, Figure 2-l). Using the dose-response data 
for the hepatocellular carcinoma in rats, EPA (1980, 198Sa) derived and 
verified an oral slope factor (ql * ) of 8.0 x 10-l (mg/kg/day)-1 for 
1,2-diphenylhydrazine. Using this slope factor, the doses associated with 
upper-bound lifetime cancer risk levels of 10-4 to 10-7 are calculated to 
be 1.3 x l0-4 to 1.3 x 10-7 mg/kg/day, respectively (Figure 2-l). 
2.2.3 Dermal Exposure
 
No studies were located regarding the following health effects in
 






















No studies were located regarding carcinogenic effects of
 
1,2-diphenylhydrazine in humans. As discussed below, inconclusive data for
 




Dermal application of an estimated 1,2-diphenylhydrazine dose of 63
 
mg/kg/day I three times a week for 442 days, caused a 22.2% incidence of
 
tumors in mice (Pliss 1974). Tumors occurred in the lung, liver, and other
 
tissues, and the tumor incidence in control mice was 17%. The significance
 
of these findings cannot be determined, as incidences of specific tumors in
 








No studies were located regarding absorption in humans or animals
 
after inhalation exposure to 1,2-diphenylhydrazine. Pulmonary absorption of
 
1,2-diphenylhydrazine by rats is suggested by detection of an unidentified
 
metabolite in the urine following intratracheal administration of
 
1,2-diphenylhydrazine in water suspension and dimethyl sulfoxide (DMSO)
 






No studies were located regarding absorption in humans after oral
 
exposure to 1,2-diphenylhydrazine. Specific information regarding absorption
 
in animals following oral exposure to 1,2-diphenylhydrazine was not located.
 
Gastrointestinal absorption of 1,2-diphenylhydrazine by rodents is indicated
 
by the occurrence of parent compound and metabolites in the urine following
 
oral treatment (Section 2.3.3) and systemic effects in oral carcinogenicity
 








No studies were located regarding absorption in humans or animals
 
after exposure to 1,2-diphenylhydrazine. The inadequately reported dermal
 
carcinogenicity study of 1,2-diphenylhydrazine summarized in Section 2.2.3.8
 
cannot be used to infer dermal absorption of 1,2-diphenylhydrazine because
 






No studies were located regarding distribution in humans or animals
 




No studies were located regarding distribution in humans or animals
 




No studies were located regarding distribution in humans or animals
 




Limited information is available on the metabolism of
 
1,2-diphenylhydrazine. In the only study involving 1,2-diphenylhydrazine as
 
the parent compound, urine of rats was analyzed for metabolites following
 
single oral, intraperitoneal, intravenous, and intratracheal doses of
 
1,2-diphenylhydrazine (Dutkiewicz and Szymanska 1973). Unchanged
 
1,2-diphenylhydrazine was detected following treatment by all routes, and
 
aniline and benzidine were identified following the oral and intraperitoneal
 
treatments. Other metabolites included two unspecified hydroxy derivatives
 
of benzidine (oral route), 2- and 4- aminophenol (intraperitoneal route),
 
and unidentified compounds (oral, intravenous, and intratracheal routes).
 
Amounts of compounds excreted were not quantitated. Two of the known
 
metabolites, aniline and benzidine, may contribute to the toxicity and/or
 
carcinogenicity of 1,2-diphenylhydrazine. The validity of the findings of
 
this study is uncertain, however, as the analytical methodology (thin-layer
 
chromatography) may have produced degradation products that were identified
 
as unchanged 1,2-diphenylhydrazine or metabolites (see Section 6.1).
 
The metabolites identified by Dutkiewicz and Szymanska (1973) are
 
consistent with a metabolic scheme proposed by Williams (1959) (Figure 2-2),
 
which is based on data for azobenzene and aniline. As summarized by NRC
 







4-aminophenol or of the nitrogen to form phenylhydroxylamine, and then is
 
conjugated to glucuronic or sulfuric acid. An oral study of azobenzene
 
with conventional and germ-free rats (Macholz et al. 1985) showed that
 
metabolism of 1,2-diphenylhydrazine to aniline resulted from the reductional
 
and hydrolytic capability of gut flora. In vitro metabolism of
 
1,2-diphenylhydrazine to aniline by rat intestinal microorganisms has been
 
demonstrated (Bolton and Griffiths 1978).
 
Benzidine is formed readily from 1,2-diphenylhydrazine by acid
 
rearrangement. It has been suggested that benzidine may be produced from
 






No studies were located regarding excretion in humans or animals after
 
inhalation exposure to 1,2-diphenylhydrazine. The presence of an
 
unidentified metabolite in the urine of rats following intratracheal
 
administration of 1,2-diphenylhydrazine in water and DMSO suspensions
 






No studies were located regarding excretion in humans after oral
 
exposure to 1,2-diphenylhydrazine. The identification of unchanged
 
1,2-diphenylhydrazine and metabolites in the urine following oral dosing of
 
rats with 1,2-diphenylhydrazine (Dutkiewicz and Szymanska 1973) indicates
 




No studies were located regarding excretion in humans or animals after
 
dermal exposure to 1,2-diphenylhydrazine.
 
2.4 RELEVANCE TO PUBLIC HEALTH
 
Death. Information regarding death in humans following exposure to
 
1,2-diphenylhydrazine by any route was not found. Some information is
 
available on lethality of orally-administered 1,2-diphenylhydrazine in
 
animals. This information, consisting of a gavage LD50 value in rats 
(Marhold et al. 1968) and an unreliable 3-day dietary lethal dose in mice 
(Schafer and Bowles 1985), indicates that single or several oral doses of 
about 1000 mg/kg/day may be lethal for rodents. Based on these data, 
1,2-diphenylhydrazine does not appear to be highly acutely toxic to humans 





Intermediate (4-week) and chronic (78-week) duration diet studies with
 
rats found that 1,2-diphenylhydrazine produced death at doses as low as 54
 
and 15 mg/kg/day, respectively (NCI 1978). These doses are substantially
 
lower than those associated with acute lethality. These data suggest that
 
prolonged ingestion of these doses of 1,2-diphenylhydrazine may be lethal
 
for humans. However, as discussed in the introduction to Section 2.8.2,
 
prolonged environmental exposure to 1,2-diphenylhydrazine is unlikely.
 
Systemic Effects. No information regarding systemic effects in humans
 
following exposure to 1,2-diphenylhydrazine by any route was found. Very
 




NCI (1978) observed a variety of nonneoplastic lesions in rats and
 
mice exposed to 1,2-diphenylhydrazine in the diet for 78 weeks, concluding
 
that ".. .none appeared to be compound-related." Evaluation of the incidence
 
data for nonneoplastic lesions, however, shows that there were
 
statistically significant increased incidences of lung interstitial
 
inflammation and liver fatty metamorphosis in treated male and female rats,
 
stomach hyperkeratosis and acanthosis in treated male rats, and liver
 
coagulative necrosis in treated female mice. Nonneoplastic liver lesions,
 
hepatocellular carcinomas and/or neoplastic liver nodules in orally-treated
 
rats and mice indicate that the liver is a target of 1,2-diphenylhydrazine
 
toxicity. Gross pathological examinations conducted in the 4-week NCI
 
(1978) diet study showed intestinal hemorrhages in mice that died. A local
 
irritative effect of 1,2-diphenylhydrazine is suggested by the occurrence of
 
the stomach hyperkeratosis/acanthosis in rats and intestinal hemorrhage in
 
mice. Since hydrazine and some hydrazine derivatives are hepatotoxic and
 
local irritants (Reinhardt and Brittelli 1981), it is possible that
 
1,2-diphenylhydrazine could cause similar effects in humans.
 
Intravenous injection of an 18.4 mg/kg dose of 1,2-diphenylhydrazine
 
did not cause methemoglobinemia in rats, although methemoglobin was formed
 
by an equimolar dose of aniline (Pfordte 1973). Information on
 
methemoglobinemia in animals following treatment with 1,2-diphenylhydrazine
 
by other routes was not located. As aniline and other aromatic amino
 
metabolites of 1,2-diphenylhydrazine (e.g., aminophenols) are
 
methemoglobinforming compounds by either oral or inhalation routes of exposure
 
(Beard and Noe 1981), it is possible that 1,2-diphenylhydrazine may cause
 
methemoglobinemia in humans. However, this would occur only if sufficient
 
aniline were formed rapidly enough to exceed the capacity of methemoglobin
 
reductase to reduce methemoglobin.
 
Immunological Effects. No studies were located regarding
 
immunological effects of 1,2-diphenylhydrazine in humans or animals by any
 
route of exposure. This lack of data precludes speculation on possible
 






Neurological Effects. No studies were located regarding neurological
 
effects of 1,2-diphenylhydrazine in humans by any route of exposure. Rats
 
and mice that were treated with lethal doses of 1,2-diphenylhydrazine in a
 
chronic (78-week) diet study did not show symptoms of toxicity or
 
histological alterations in the brain (NCI 1978), but no behavioral or
 
neurological evaluations were conducted. The insufficiency of these data
 




Developmental Effects. No studies were located regarding
 
developmental effects of 1,2-diphenylhydrazine in humans or animals by any
 
route of exposure. This lack of data precludes speculation on possible
 
developmental toxicity of 1,2-diphenylhydrazine in humans.
 
Reproductive Effects. No studies were located regarding reproductive
 
effects of 1,2-diphenylhydrazine in humans by any route of exposure. Rats and
 
mice that were treated with lethal doses of 1,2-diphenylhydrazine in a chronic
 
(78-week) diet study did not show histological alterations in reproductive
 
organs (NCI 1978), but reproductive function was not evaluated. The
 
insufficiency of these data precludes making any conclusions regarding
 
reproductive toxicity of 1,2-diphenylhydrazine in humans.
 
Genotoxic Effects. No studies were located regarding the genotoxicity of
 
1,2-diphenylhydrazine in humans by any route of exposure. A limited number of
 
assays have been conducted using bacteria, mammalian cell and whole animal
 
systems. As indicated in Table 2-2, 1,2-diphenylhydrazine was mutagenic in
 
Salmonella tynhimurium, but not in Escherichia coli, and produced chromosome
 
aberrations and sister chromatid exchanges in Chinese hamster cells. An
 
exogenous metabolic activation system was necessary for expression of the
 
aforementioned effects. In in vivo studies (Table 2-3), 1,2-diphenylhydrazine
 
inhibited testicular DNA synthesis in mice when administered as a single 100
 
mg/kg intraperitoneal injection, but did not cause sex-linked recessive lethal
 
mutations in Drosophila when administered in the feed or by injection.
 
Although only limited data are available, the weight of evidence
 
indicates that 1,2-diphenylhydrazine is genotoxic in animals. In
 
particular, positive results were obtained in all assays with mammalian
 
systems. Overall, the available evidence suggests that 1,2- diphenylhydrazine
 
may cause chromosomal damage or other genotoxic effects in humans.
 
Cancer. Information regarding the carcinogenicity of
 
1,2-diphenylhydrazine in humans by any route of exposure was not located.
 
In animals, significantly increased incidences of hepatocellular carcinomas,
 
neoplastic liver nodules, mammary adenocarcinomas, Zymbal's gland carcinomas
 
and adrenal pheochromocytomas occurred in rats and/or mice treated with
 
1,2-diphenylhydrazine in the diet for 78 weeks (NCI 1978). Other
 








in rats (Pliss 1974; Marhold et al. 1978), dermal treatment in mice (Pliss
 
1974), and subcutaneous or intraperitoneal injection in rats and mice
 
(Spitz et al. 1950; Genin et al. 1975; Pliss 1974; Shabad and Genin 1975;
 
Kurlyandskiy et al. 1976; Maronpot et al. 1986), are inconclusive due to
 
inadequate reporting and other limitations. Although inconclusive, most of
 
these studies reported tumors at sites that are generally consistent with
 
sites of tumors in the NCI (1978) bioassay (e.g., liver, mammary gland,
 
adrenal gland, and Zymbal's gland).
 
The NCI (1978) bioassay, which demonstrated carcinogenicity in two
 
species, provides sufficient evidence of carcinogenicity of
 
1,2-diphenylhydrazine in animals. Biotransformation products of
 
1,2-diphenylhydrazine include aniline and benzidine, which are known
 
carcinogens in animals (both chemicals) and humans (benzidine) (EPA
 
1988b,c). Based on the animal evidence for carcinogenicity from the NCI
 
(1978) bioassay and the carcinogenicity of its metabolites,
 
1,2-diphenylhydrazine is likely to be carcinogenic in humans.
 
2.5 BIOMARKERS OF EXPOSURE AND EFFECT
 
Biomarkers are broadly defined as indicators signaling events in
 
biologic systems or samples. They have been classified as markers of
 
exposure, markers of effect, and markers of susceptibility (NAS/NRC, 1989).
 
A biomarker of exposure is a xenobiotic substance or its metabolite(s)
 
or the product of an interaction between a xenobiotic agent and some target
 
molecule or cell that is measured within a compartment of an organism
 
(NAS/NRC 1989). The preferred biomarkers of exposure are generally the
 
substance itself or substance-specific metabolites in readily obtainable
 
body fluid or excreta. However, several factors can confound the use and
 
interpretation of biomarkers of exposure. The body burden of a substance
 
may be the result of exposures from more than one source. The substance
 
being measured may be a metabolite of another xenobiotic (e.g., high urinary
 
levels of phenol can result from exposure to several different aromatic
 
compounds). Depending on the properties of the substance (e.g., biologic
 
half-life) and environmental conditions (e.g., duration and route of
 
exposure), the substance and all of its metabolites may have left the body
 
by the time biologic samples can be taken. It may be difficult to identify
 
individuals exposed to hazardous substances that are commonly found in body
 
tissues and fluids (e.g., essential mineral nutrients such as copper, zinc
 
and selenium). Biomarkers of exposure to 1,2-diphenylhydrazine are
 
discussed in Section 2.5.1.
 
Biomarkers of effect are defined as any measurable biochemical,
 
physiologic, or other alteration within an organism that, depending on
 
magnitude, can be recognized as an established or potential health
 
impairment or disease (NAS/NRC 1989). This definition encompasses
 
biochemical or cellular signals of tissue dysfunction (e.g., increased liver
 






as well as physiologic signs of dysfunction such as increased blood pressure
 
or decreased lung capacity. Note that these markers are often not substance
 
specific. They also may not be directly adverse, but can indicate potential
 
health impairment (e.g., DNA adducts). Biomarkers of effects caused by
 
1,2-diphenylhydrazine are discussed in Section 2.5.2.
 
A biomarker of susceptibility is an indicator of an inherent or
 
acquired limitation of an organism's ability to respond to the challenge of
 
exposure to a specific xenobiotic. It can be an intrinsic genetic or other
 
characteristic or a preexisting disease that results in an increase in
 
absorbed dose, biologically effective dose, or target tissue response. If
 
biomarkers of susceptibility exist, they are discussed in Section 2.7,
 
"POPULATIONS THAT ARE UNUSUALLY SUSCEPTIBLE."
 
2.5.1 Biomarkers Used to Identify or Quantify Exposure to 1,2­
Diphenylhydrazine
 
No studies were located regarding biomarkers of exposure to 1,2­
diphenylhydrazine. The metabolites of 1,2-diphenylhydrazine were identify
 
in one study (Dutkiewicz and Szymanska); however, the validity of the
 
findings is uncertain because of the analytical methodology used (see
 
Section 2.3.3 Metabolism). No enzymatic changes that could be used as
 
biomarkers of 1,2-diphenylhydrazine exposure are known.
 
2.5.2 Biomarkers Used to Characterize Effects Caused by 1,2-Diphenylhydrazine
 
No biomarkers of effects were identified for 1,2-diphenylhydrazine
 
exposure. No specific alterations in the organism that could be recognized
 




2.6 INTERACTIONS WITH OTHER CHEMICALS
 
A carcinogenicity study was reported in which groups of rats were
 
given weekly subcutaneous injections of 1,2-diphenylhydrazine (20 mg), or
 
1,2-diphenylhydrazine (20 mg) concurrently with benzidine sulfate (15 mg)
 
for life (Genin et al. 1975). Combined incidences of tumors (injection
 
site, liver, and other sites) were increased and the mean tumor latent
 
period was decreased in the group with combined 1,2-diphenylhydrazine and
 
benzidine sulfate exposure.. It is unclear whether these findings provide
 
evidence for an interaction between 1,2-diphenylhydrazine and benzidine or
 
additive effects of two carcinogens. The results of this study were also
 
reported by Shabad and Genin (1975) and Kurlyandskiy et al. (1976).
 
Concurrent exposure to 1,2-diphenylhydrazine and benzidine could occur
 
during benzidine production, since 1,2-diphenylhydrazine is used as a
 
starting material in the production of benzidine, which is a degradation or
 






2.7 POPULATIONS THAT ARE UNUSUALLY SUSCEPTIBLE
 
No populations with unusual susceptibility to health effects of
 
1,2-diphenylhydrazine have been identified. It is possible that people with
 
chronic liver disease or possibly compromised hepatic function (e.g., very
 
young or very old people, alcoholics) might be unusually susceptible to
 




2.8 ADEQUACY OF THE DATABASE
 
Section 104(i)(5) of CERCLA directs the Administrator of ATSDR (in
 
consultation with the Administrator of EPA and agencies and programs of the
 
Public Health Service) to assess whether adequate information on the health
 
effects of 1,2-diphenylhydrazine is available. Where adequate information
 
is not available, ATSDR, in conjunction with the National Toxicology Program
 
(NTP) , is required to assure the initiation of a program of research
 
designed to determine the health effects (and techniques for developing
 
methods to determine such health effects) of 1,2-diphenylhydrazine.
 
The following categories of data needs have been identified by a joint
 
team of scientists from ATSDR, NTP, and EPA. They are defined as
 
substancespecific informational needs that, if met would reduce or eliminate
 
the uncertainties of human health assessment. In the future, the identified
 
data needs will be evaluated and prioritized, and a substance-specific
 
research agenda will be proposed.
 
2.8.1 Existing Information on Health Effects of 1,2-Diphenylhydrazine
 
The existing data on health effects of inhalation, oral, and dermal
 
exposure of humans and animals to 1,2-diphenylhydrazine are summarized in
 
Figure 2-3. The purpose of this figure is to illustrate the existing
 
information concerning the health effects of 1,2-diphenylhydrazine. Each
 
dot in the figure indicates that one or more studies provide information
 
associated with that particular effect. The dot does not imply anything
 
about the quality of the study or studies. Gaps in this figure should not
 
be interpreted as "data needs" information.
 
Information regarding health effects of 1,2-diphenylhydrazine in
 
humans is not available. Except for one dermal study, health effects of
 
1,2-diphenylhydrazine in animals have been investigated only in oral
 
exposure studies. As indicated in Figure 2-3, animal oral data are
 
available for lethality, systemic effects due to intermediate and chronic
 
duration exposure, and genotoxicity and cancer. These data indicate that
 
oral exposure to 1,2-diphenylhydrazine was life-shortening, hepatotoxic,
 
irritating to the stomach, and carcinogenic to rats and/or mice. Limited
 
animal data are available for neurologic and reproductive effects due to
 







2.8.2 Identification of Data Needs
 
Acute-Duration Exposure. Information is not available on the health
 
effects of 1,2-diphenylhydrazine resulting from inhalation exposure in
 
humans or animals. Because 1,2-diphenylhydrazine is a solid with a low
 
vapor pressure at ambient temperatures, it is highly unlikely that
 
inhalation exposure to this chemical in the vapor state would occur (Chapter
 
5). However, the possibility of inhalation exposure to dusts of 1,2­
diphenylhydrazine either free or adsorbed to soil is conceivable.
 
Therefore, acute studies of inhalation exposure to dusts of 1,2­
diphenylhydrazine could be designed to provide information on possible toxic
 
effects and exposure levels that cause effects. No studies were located
 
regarding acute oral exposure in humans. The only pertinent acute exposure
 
toxicity studies of 1,2-diphenylhydrazine were conducted in rats; these
 
consist of an oral LD50 assay and methemoglobin determination following 
intravenous treatment. Additional acute oral exposure studies could 
corroborate the LD50, identify systemic effects, and provide information on 
thresholds of effects as well as interspecies differences. However, 
although ingestion of 1,2-diphenylhydrazine-contaminated soil from waste 
sites is conceivable, extensive oral studies appear to be unwarranted as the 
possibility of exposure from ingestion of contaminated soil seems unlikely, 
and exposure via drinking water is essentially nonexistent because of the 
rapid oxidation of 1,2-diphenylhydrazine in water (Chapter 5). Because of 
the lack of dose-effect information, no MRL was derived. Pharmacokinetic 
data are insufficient for identification of target organs across routes of 
exposure. No studies were located regarding acute dermal exposure in humans 
or animals. Acute dermal studies of 1,2-diphenylhydrazine with animals 
could provide information on skin and eye irritation, lethality, and other 
toxic effects. Dermal studies of 1,2-diphenylhydrazine appear to be most 
relevant, as dermal exposure is a likely route of environmental exposure. 
As discussed in Chapter 5, dermal exposure via direct chemical contact or 
contact with contaminated soil is possible at hazardous waste sites, where 
high concentrations of crystalline 1,2-diphenylhydrazine could occur. 
Intermediate-Duration Exposure. No information was located regarding
 
intermediate-duration inhalation exposure to 1,2-diphenylhydrazine in humans
 
or animals. As discussed for acute-duration exposure, 1,2-diphenylhydrazine is
 
a solid with a low vapor pressure at ambient temperature, which makes
 
inhalation exposure to this chemical in the vapor state unlikely. However, the
 
possibility of inhalation exposure to dusts of 1,2-diphenylhydrazine either
 
free or adsorbed to soil is conceivable. Therefore, intermediateduration
 
studies of inhalation exposure to dusts of 1,2-diphenylhydrazine could be
 
designed to provide information on possible toxic effects and exposure levels
 
that cause effects. A limited number of intermediateduration oral studies
 
provide information on lethality and/or gross pathology in rats and mice.
 
Because of the lack of reliable information about dose-relationship, no MRL
 
was derived. Pharmacokinetic data were insufficient for identification of
 






Additional studies examining histology or other sensitive endpoints could
 
elucidate systemic effects and thresholds of toxicity. Intermediateduration
 
dermal studies examining systemic toxicity in animals could provide
 
information on whether repeated dermal exposure of humans poses a threat of
 
toxic effects. This information would be useful for an evaluation of health
 
risk in populations living near hazardous waste sites that might be
 
repeatedly exposed to 1,2-diphenylhydrazine-contaminated soil.
 
Chronic-Duration Exposure and Cancer. No studies were located
 
regarding chronic inhalation exposure to 1,2-diphenylhydrazine in humans or
 
animals. As discussed for acute- and intermediate-duration exposure,
 
1,2-diphenylhydrazine is a solid with a low vapor pressure at ambient
 
temperature, which makes inhalation exposure this chemical in the vapor
 
state unlikely. However, the possibility of inhalation exposure to dusts of
 
1,2-diphenylhydrazine either free or adsorbed to soil is conceivable.
 
Therefore, chronic-duration studies of inhalation exposure to dusts of
 
1,2-diphenylhydrazine could be designed to provide information on possible
 
toxic effects and exposure levels that cause effects. The NCI (1978)
 
bioassay of 1,2-diphenylhydrazine provides the only sufficient chronic oral
 
toxicity data for this chemical. This study was not, however, subjected to
 
the peer review process used for current NTP bioassays, and it inadequately
 
evaluated nonneoplastic effects. Additional studies would be particularly
 
useful for corroborating and more fully characterizing 1,2-diphenylhydrazine­
induced systemic toxicity. In particular, more studies could provide
 
information on cause(s) of death due to chronic exposure, and delineate
 
carcinogenic and noncarcinogenic doses. No studies were located regarding
 
toxic effects after chronic dermal exposure to 1,2-diphenylhydrazine in humans
 
or animals. Because of the lack of reliable data, no MRL for chronic exposure
 
was derived. Pharmacokinetic data were insufficient for identification of
 
target organs across routes of exposure. More information regarding chronic
 
dermal exposure would be useful for possible extrapolation of results to
 
humans that may be exposed to 1,2-diphenylhydrazine near hazardous waste sites
 
for a long period of time.
 
The paucity of systemic toxicity data for this chemical appears to be
 
related to primary interest in testing for carcinogenicity. Treatment related
 
neoplasms developed in rats and mice that were treated with 1,2­
diphenylhydrazine in a diet. An inconclusive chronic dermal carcinogenicity
 
study of 1,2-diphenylhydrazine with mice was available. The development of
 
neoplasia was reported in the exposed group. The results from the controls
 
were not, however, provided. The available data, although scarce, indicate a
 
possible carcinogenic potential for 1,2-diphenylhydrazine. This finding is
 
supported by some genotoxicity studies. Additional chronic dermal studies
 




Genotoxicity. A limited number of in vitro assays with bacteria and
 
mammalian cells and an in vivo assay with mice indicate that 1,2­






conducted with the exception of assays with Salmonella, and mutation in
 
mammalian systems and genotoxicity in human cells have not been evaluated.
 
Additional studies, particularly involving mammalian systems and providing
 
information on the potential for heritable mutations, would add to the
 
database on genotoxicity and validate available information.
 
Reproductive Toxicity. The unremarkable histology of the reproductive
 
organs of the rats and mice in the NCI (1978) bioassay provides limited
 
information on the lack of reproductive toxicity of 1,2-diphenylhydrazine.
 
Multigeneration or continuous breeding studies in animals would provide a
 




Developmental Toxicity. It is not known whether 1,2-diphenylhydrazine
 
crosses the placenta, but there is no reason to assume that it (or its
 
metabolites) would not do so. Developmental studies in mammals would provide
 
information on possible fetotoxic and teratogenic effects of 1,2­
diphenylhydrazine that might be relevant to humans.
 
Immunotoxicity. No histopathological effects on immunological organs
 
and tissues of rats and mice were found in the NCI (1978) chronic oral
 
bioassay of 1,2-diphenylhydrazine. Adequate evaluation of immunotoxic
 
potential is precluded by a lack of specific immunotoxicity tests of
 
1,2-diphenylhydrazine. Dermal sensitization tests in animals might provide
 




Neurotoxicity. No clinical signs of central nervous system toxicity or
 
histological alterations of nervous system organs and tissues were observed in
 
rats or mice in the NCI (1978) chronic oral bioassay. Tests for
 
neurotoxicity in animals may be appropriate if there is clinical evidence of
 




Epidemiological and Human Dosimetry Studies. Health effects of
 
1,2-diphenylhydrazine have not been described in humans. As discussed in
 
Chapter 5, the potential for environmental exposure to 1,2-diphenylhydrazine
 
is extremely low. Although dermal exposure to 1,2-diphenylhydrazine could
 
occur at a contaminated waste site, it is highly unlikely that segments of
 
the general population will be exposed to 1,2-diphenylhydrazine.
 
If 1,2-diphenylhydrazine or its metabolites in urine can be correlated
 
with dermal exposure in humans, it may be possible to monitor humans for
 
exposure. If toxic effects resulting from dermal exposure to
 
1,2-diphenylhydrazine are identified in humans, it may then be possible to
 








Biomarkers of Exposure and Effect. No biomarkers are known that are
 
specific for 1,2-diphenylhydrazine exposure. Continued efforts to devise
 
more sensitive and more specific early biomarkers of disease (especially
 
cancer) would be valuable.
 
Absorption, Distribution, Metabolism, Excretion. The general
 
metabolic pathways of 1,2-diphenylhydrazine are identifiable based on
 
limited evidence for 1,2-diphenylhydrazine in oral, intratracheal, and
 
injection experiments with rats (Dutkiewicz and Szymanska 1973), metabolism
 
data for azobenzene (which is metabolized to 1,2-diphenylhydrazine), and
 
metabolism data for aniline (an initial metabolite). The relative
 
contribution of the different pathways is not established. Although oral
 
absorption of 1,2-diphenylhydrazine and urinary excretion of
 
1,2-diphenylhydrazine and its metabolites are apparent, there is no
 
information on the rate and extent of absorption, or excretion, or tissue
 
distribution following oral exposure. Investigations of the toxicokinetics
 
of 1,2-diphenylhydrazine following dermal exposure have not been conducted.
 
Additional studies of absorption, distribution, metabolism, and excretion in
 
animals by the oral and dermal routes of exposure would provide information
 
needed for sufficient characterization of the toxicokinetics of
 
1,2-diphenylhydrazine. Studies addressing differences in metabolism between
 
oral and dermal routes would be particularly informative, as benzidine may
 
be formed by acidity in the stomach.
 
Comparative Toxicokinetics. No data are available to determine if
 
there are differences in the toxicokinetics of 1,2-diphenylhydrazine among
 
species. Toxicokinetic studies with different species could help explain
 
observed differences in toxicity and carcinogenicity between rats and mice,
 
and help identify the animal species that serves as the best model for
 













Data pertaining to the chemical identity of 1,2-diphenylhydrazine
 
listed in Table 3-1.
 
3.2 PHYSICAL AND CHEMICAL PROPERTIES
 
The physical and chemical properties of 1,2-diphenylhydrazine are
 











1,2-Diphenylhydrazine is produced in the stepwise reduction of
 
nitrobenzene by the action of iron or zinc powder in caustic solution (e.g.,
 
caustic soda, alcoholic alkaline) first to azoxybenzene, then azobenzene,
 
and finally 1,2-diphenylhydrazine (Sandridge and Staley 1978). A batch
 
process is used in which a caustic soda solution is added to a heated vessel
 
charged with nitrobenzene and iron borings. Additions of iron in caustic
 
soda solution are made to continue the reaction. When the reaction is
 
complete, separation of the 1,2-diphenylhydrazine from the iron sludge is
 
accomplished by solvent extraction or by alternative methods, such as
 
stopping the reaction at the azobenzene step and performing the final
 
reduction in a zinc-alcoholic alkali solution followed by filtration and
 
washing of the sodium zincate mass.
 
No recent information was located regarding production volumes of
 
1,2-diphenylhydrazine. The U.S. International Trade Commission last
 
reported production of 1,2-diphenylhydrazine for the 1978 production year
 
(USITC 1979). In that year, Bofors Lakeway, Muskegon, MI, reportedly
 
produced and isolated 1,2-diphenylhydrazine, but no volumes were published.
 
The USITC will not publish production volumes of chemicals for which there
 
are less than three manufacturers. No producers have been reported by the
 
USITC since 1978, indicating either that less than 5000 pounds were produced
 






No information concerning the importation or exportation of
 




One of the major uses of 1,2-diphenylhydrazine is as a starting
 
material in the production of benzidine; however, it is no longer produced
 
in the United States. 1,2-Diphenylhydrazine rearranges to benzidine upon
 
treatment with strong acid; benzidine is used by the dye industry for the
 
production of benzidine-based dyes including many of the Direct dyes (e.g.,
 
Direct Red 28, Direct Black 4, Direct Blue 2) (Ferber 1978; Lurie 1964).
 
Fabricolor, the last producer of benzidine based dyes, discontinued
 
production in 1988 (Personal communication, Alvarez 1989).
 
1,2-Diphenylhydrazine is used for the production of the drugs
 
phenylbutazone (trade name Butazolidin, an anti-inflammatory agent) and
 
sulfinpyrazone (trade name Anturane, a uricosuric agent for the treatment of
 
gouty arthritis) (Barnhart 1988; Hughes 1981; Kornis 1982). These drugs are
 
made by the condensation of 1,2-diphenylhydrazine with malonic acid
 
derivatives to form pyrazolidinedione structures. It is not clear from the
 




4. PRODUCTION, IMPORT, USE, AND DISPOSAL
 






Very little information was located in the literature concerning the
 
disposal of 1,2-diphenylhydrazine. Dietrich et al. (1985) reported that wet
 
air oxidation (heating wastewater under pressure with the addition of an
 
oxygen-containing gas such as air) would remove 99.88% of the
 
1,2-diphenylhydrazine in the water (initial concentration, 5000 mg/L). Wet
 
air oxidation can effectively treat aqueous waste streams that are too
 
dilute to incinerate, yet too toxic to treat using biological processes.
 
Results of treatment by wet air oxidation are in keeping with the
 
observation that 1,2-diphenylhydrazine oxidizes on standing to azobenzene
 
(Riggin and Howard 1979). Information regarding the amount of
 










1,2-Diphenylhydrazine oxidizes rapidly in the environment under aerobic
 
conditions, with a half-life in water as short as 15 minutes. This rapid
 
oxidation coupled with the lack of straightforward sampling methods makes the
 
assessment of the literature difficult. For example, while a few
 
monitoring papers report the detection of 1,2-diphenylhydrazine in the
 
environment, their analytical methodology suggests that it is unlikely that
 
1,2-diphenylhydrazine would have been detected even if present. In
 
addition, little information is available to assess the potential for
 
environmental contamination, making the estimation of environmental releases
 
difficult. Therefore, not only is the significance of reported
 
environmental concentrations difficult to interpret, environmental
 
concentrations are difficult to predict. The fate, transport, and
 
distribution of 1,2-diphenylhydrazine in the environment are uncertain.
 
1,2-Diphenylhydrazine has been reported at 7 of 1177 sites in the National
 
Priority List database (ATSDR 1990); the frequency of these sites within the
 
United States can be seen in Figure 5-l.
 




No information concerning the release of 1,2-diphenylhydrazine to air 
was located in the literature. The vapor pressure of 1,2-diphenylhydrazine 
is low (2.6 x 10-5 mmHg at 25 C), indicating that little 1,2-diphenylhydrazine 
will volatilize from manufacturing and use operations. Dust generated from the 
loading and off-loading of 1,2-diphenylhydrazine during use may cause local 
atmospheric concentrations. If present in water, 
1,2-diphenylhydrazine will probably oxidize to azobenzene before it 
volatilizes. Volatilization of 1,2-diphenylhydrazine is not expected to be 
an environmentally relevant fate process given the low Henry's Law constant 
(9.42 x 10-8 atm-m3 mol-1). 
5.2.2 Water
 
No information concerning the release of 1,2-diphenylhydrazine to water
 
was located in the literature. If discharged to water, detectable
 
concentrations will probably persist for only a short time, since the halflife
 
of (100 µg/L) 1,2-diphenylhydrazine in wastewater is about 15 minutes (Riggin 
and Howard 1979, 1982) 
5.2.3 Soil
 
No information concerning the release of 1,2-diphenylhydrazine to soil
 
was located in the literature. The manufacturing process for
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compounds, probably along with small amounts of unextracted
 
1,2-diphenylhydrazine. Some of this material may be disposed of in
 
landfills, but no information is available concerning the
 




5.3.1 Transport and Partitioning
 
No information concerning the transport and partitioning of 
1,2-diphenylhydrazine in the environment was located in the literature. In 
water, 1,2-diphenylhydrazine is not expected to volatilize because of its 
rapid oxidation in aerated water (near-surface water) to azobenzene and its 
low calculated Henry's Law constant (9.42 x 10-8 atm-m3 mol-l) (Lyman et al. 
1982). The calculated log Koc (2.76) suggests that 1,2-diphenylhydrazine 
may sorb to sediments or suspended particles. This is based on the analysis 
of Kenaga (1980), who stated that chemicals with a Koc <lOO tend to be 
mobile in soil, while those with a Koc >lOOO tend to sorb. In soil, 
1,2-diphenylhydrazine is not expected to leach to groundwater, based on its 
physical and chemical properties (i.e., 1,2-diphenylhydrazine reacts rapidly 
under environmental conditions and, based on its Koc, will not rapidly leach 
downward in the soil column). 




No studies were located regarding the rates or products of reaction of
 
1,2-diphenylhydrazine in the atmosphere. Based on its behavior in aerated
 
water, 1,2-diphenylhydrazine may react rapidly in air to form azobenzene as
 
well as other products resulting from the abstraction of a hydrogen from a
 
nitrogen by hydroxyl radical. Atkinson (1987) developed a method to
 
estimate the hydroxyl radical (HO•) reaction rate based on structure. 
this method, an overall reaction rate of 211 x l0-l2 cm 3 molecule-1 sec -1 
was calculated, which yields a half-life of less than 2 hours for an 
atmospheric HO•. concentration of 0.5 x l06 molecules cm-3. This is an 
estimated annually averaged concentration for a 24-hour period (Atkinson 
1985). 1,2-Diphenylhydrazine also absorbs light above 290 nm (Sadtler
 
Index, no date) and may be susceptible to photolysis. No information was
 




Very little information was located concerning the fate of
 
1,2-diphenylhydrazine in water. Riggin and Howard (1979, 1982) reported the
 
results of a study on the stability of 1,2-diphenylhydrazine in a number of
 
solvents including distilled water and wastewater. In distilled water at pH
 
values of 2, 4.7, 7, and 10 and at 4°C or at room temperature, less than 10%
 
of the initial 10 µg/L of 1,2-diphenylhydrazine remained in the water after 
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1 day. At pH 2, 1,2-diphenylhydrazine degraded to benzidine, while at pH 7
 
it degraded to an unidentifiable oxidizable product. At pH 10,
 
1,2-diphenylhydrazine degraded to azobenzene, and at pH 4.7, it degraded
 
into two unidentifiable products, which were not azobenzene or benzidine.
 
In secondary municipal sewage effluent, Riggin and Howard (1979, 1982)
 
reported that 100 µg/L of 1,2-diphenylhydrazine had a half-life of about 15 
minutes in the presence of oxygen, and about 60 minutes when no oxygen was 
present. These results suggest that 1,2-diphenylhydrazine is unlikely to 
persist in the environment, particularly under aerobic conditions. 
Weber and Wolfe (1986, 1987) reported that azobenzene, when incubated
 
in air with four anaerobic lake sediments containing about 2-4% organic
 
matter, was reduced to aniline with a reaction half-life of about 2700-5700
 
minutes, depending on the source and date of specimen collection.
 
1,2-Diphenylhydrazine was not detected as an intermediate. The authors
 




In reporting the same data, Tabak et al. (1981a,b) and Patterson and
 
Kodukala (1981) stated that 5 or 10 mg/L of 1,2-diphenylhydrazine was
 
degraded up to 80% when initially cultured with settled domestic wastewater.
 
This degradation rate, however, was reduced to 40% in the case of the 10
 
mg/L concentration, after the third subculture. The authors suggested that
 
a de-adaptive and toxification process was occurring with
 
1,2-diphenylhydrazine. It is unclear if the analytical methods used by
 
these authors would have been able to detect 1,2-diphenylhydrazine if
 
present. Both dissolved organic carbon and gas chromatography (GC) analyses
 
were performed on the samples. Considering the sample preparation
 
procedures, however, the compound detected might not have been
 




No information concerning the fate of 1,2-diphenylhydrazine in soil was
 
located in the literature. Based on the fate of 1,2-diphenylhydrazine in
 
water and sediment, detectable concentrations probably will not persist for
 
long periods, but this may depend on the initial concentration.
 
5.4 LEVELS MONITORED OR ESTIMATED IN THE ENVIRONMENT
 
The rapid oxidation of 1,2-diphenylhydrazine in water to form
 
azobenzene and other compounds makes its sampling and analysis difficult.
 
Storing a sample containing 1,2-diphenylhydrazine for even short periods can
 
result in complete oxidation; in gas chromatography, 1,2-diphenylhydrazine
 
is oxidized to azobenzene upon injection onto the chromatographic column
 
(Riggin and Howard 1982). Therefore, unless sampling and analysis are
 
performed under conditions that will prevent oxidation or unless
 
concentrations of 1,2-diphenylhydrazine in the sample are very high,
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(Ahuja et al. 1988; Riggin and Howard 1979). It is doubtful that the
 
concentrations measured reflect on the concentrations present in the sample
 
at the time of collection (i.e., measured concentrations would
 




No ambient air monitoring for 1,2-diphenylhydrazine was located in the
 
literature. This may be due to both the rapid oxidation of
 
1,2-diphenylhydrazine and its low vapor pressure, which limit the amount of
 
1,2-diphenylhydrazine entering the atmosphere. In addition, no information
 






Two reported identifications of 1,2-diphenylhydrazine in water samples
 
were located in the literature. Melton et al. (1981) reported that
 
1,2-diphenylhydrazine was present in Cincinnati, OH, drinking water (river
 
water treated by coagulation, sand filtration, and chlorination).
 
1,2-Diphenylhydrazine was reported at a concentration of 1 ng/L. Since the
 
sample preparation involved aeration and the original sample was
 
chlorinated, it is unclear if the detected material was 1,2-diphenylhydrazine.
 
Riggin and Howard (1982) found that, in addition to injection onto a GC
 
column, either chlorination or aeration of a sample resulted In total
 
disappearance of 1,2-diphenylhydrazine. Tang et al. (1983) reported 1,2­
diphenylhydrazine in coal gasification wastewater at concentrations of 0.149
 
and 1.786 µg/L. Sample preparation in this case involved separation into 
classes by pH, liquid-liquid extraction, concentration, and gas 
chromatography/mass spectroscopy (GC/MS) analysis. No precautions were taken 
to reduce the aeration of the sample. Also, the analytical procedure indicates 
that no 1,2-diphenylhydrazine would have been able to survive the conditions 
of the sample preparation and the detection may be of another chemical or of 
1,2-diphenylhydrazine from another source (e.g., decomposition of another 
compound to 1,2-diphenylhydrazine). 
Hall et al. (1985) reported that no 1,2-diphenylhydrazine (less than 
1 µg/L) was detected in the Nanticoke River near the Chesapeake Bay. The 
analytical method involved liquid-liquid extraction, concentration, and 
analysis by GC/MS. The Contract Laboratory Program statistical database 
(queried April 13, 1987) reported that 1,2-diphenylhydrazine has been 
detected in water at 1 of 357 hazardous waste sites at a concentration of 
96 ppb (CLPSDB 1987), and has been reported at 7 of 1177 sites in the 
National Priority List database (ATSDR 1990). The U.S. EPA Contract 
Laboratory Program uses GC methods to analyze the contaminants of interest. 
Since 1,2-diphenylhydrazine oxidizes to azobenzene in the GC injector port 
and both 1,2-diphenylhydrazine and azobenzene have the same GC retention 
time and mass spectra, reports of 1,2-diphenylhydrazine from the Contract 
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Laboratory Program may actually represent detections of 1,2-diphenylhydrazine,
 




1,2-Diphenylhydrazine has been identified in soil only at hazardous
 
waste sites. The Contract Laboratory Program statistical database (queried
 
April 13, 1987) reported that 1,2-diphenylhydrazine has been detected in the
 
soil at 2 of 357 hazardous waste sites in both cases at 18,200 ppm (CLPSDB
 
1987). The Contract Laboratory Program uses GC methods to analyze the
 
contaminants of interest. As discussed in Section 5.4.2, this may actually
 
represent detections of either 1,2-diphenylhydrazine or azobenzene (see
 
Chapter 6 for more details). Furthermore, the fact that identical
 






1,2-Diphenylhydrazine has been assayed but not detected in fish samples
 
from the Great Lakes area. Camanzo et al. (1987) reported that no
 
1,2-diphenylhydrazine was detected in fish samples from 13 Lake Michigan
 
tributaries and Grand Traverse Bay fish. Analyses were made by GC/MS and no
 
detection limits were given. Similarly, DeVault (1985) reported that a
 
GC/MS did not identify any of the peaks present in fish samples from Great
 
Lakes Harbors and Tributaries as 1,2-diphenylhydrazine.
 
Phenylbutazone and sulfinpyrazone can hydrolyze to yield
 
1,2-diphenylhydrazine and these drugs may contain some 1,2-diphenylhydrazine
 
(Ahuja et al. 1988; Fabre et al. 1984; Matsui et al. 1983). Phenylbutazone
 
is a drug used for the treatment of inflammatory conditions (e.g.,
 
arthritis) and sulfinpyrazone is used to treat gouty arthritis. Although
 
potential exists for exposure to 1,2-diphenylhydrazine via from treatment
 




5.5 GENERAL POPULATION AND OCCUPATIONAL EXPOSURE
 
Virtually no information concerning general population or occupational
 
exposure was located in the literature. General population exposure may
 
come from those on phenylbutazone or sulfinpyrazone therapy, since these
 
drugs may contain some 1,2-diphenylhydrazine (Fabre et al. 1984; Matsui
 
et al. 1983). The National Institute for Occupational Safety and Health
 
(NIOSH), National Occupational Exposure Survey (NOES) reported as of May
 
1988 that 977 total employees and 154 female employees are potentially
 




The available database limits analysis of exposures in two ways.
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processes used in the production of phenylbutazone and sulfinpyrazone, the
 
two drugs that use 1,2-diphenylhydrazine as a starting material. A better
 
understanding of these processes would allow the estimation of worker
 
exposure potentials. Second, dye manufacturers in the United States no
 
longer produce benzidine based dyes (the last manufacturer stopped
 
production in 1988) and the number of workers potentially exposed to
 
1,2-diphenylhydrazine is now less than at the time of the NOES survey cited
 
above. Thus, the survey may no longer accurately reflect the number of
 
workers potentially exposed to 1,2-diphenylhydrazine.
 
5.6 POPULATIONS WITH POTENTIALLY HIGH EXPOSURE
 
The only populations with potentially high exposure appear to be
 
persons receiving phenylbutazone or sulfinpyrazone therapy, those living
 
near hazardous waste sites, and those in occupations that manufacture or use
 
1,2-diphenylhydrazine. Very little information concerning these
 




5.7 ADEQUACY OF THE DATABASE
 
Section 104(i)(5) of CERCLA, directs the Administrator of ATSDR (in
 
consultation with the Administrator of EPA and agencies and programs of the
 
Public Health Service) to assess whether adequate information on the health
 
effects of 1,2-diphenylhydrazine is available. Where adequate information
 
is not available, ATSDR, in conjunction with the NTP, is required to assure
 
the initiation of a program of research designed to determine the health
 




The following categories of possible data needs have been identified by
 
a joint team of scientists from ATSDR, NTP, and EPA. They are defined as
 
substance-specific informational needs that, if met would reduce or
 
eliminate the uncertainties of human health assessment. In the future, the
 
identified data needs will be evaluated and prioritized, and a
 
substance-specific research agenda will be proposed.
 
5.7.1 Identification of Data Needs
 
Physical and Chemical Properties. Physical and chemical properties are
 
essential for estimating the partitioning of a chemical in the environment.
 
Data are available for only a few physical and chemical properties of
 
1,2-diphenylhydrazine, and most of these have limited experimental
 
descriptions. Therefore, an evaluation of the accuracy of the data is
 
difficult. Specifically, measured solubility, vapor pressure, Koc, pKa, and
 
Henry's Law constant at environmentally significant temperatures would help
 
to remove any doubt concerning the accuracy of the partitioning estimates,
 
especially in circumstances where 1,2-diphenylhydrazine does not oxidize
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basis of much of the input requirements for environmental models that
 
predict the behavior of a chemical under specific conditions including
 
hazardous waste landfills. In addition, the uncertainty in these
 
measurements can be used to estimate the sensitivity of these properties in
 
determining the overall fate of 1,2-diphenylhydrazine in the environment.
 
Production, Use, Release, and Disposal. Production methods for
 
1,2-diphenylhydrazine are well described in the literature (including the
 
patent literature); there does not appear to be a need for further
 
information in this area. Uses of 1,2-diphenylhydrazine are documented but
 
no recent production figures or detailed descriptions of uses are available.
 
This information is useful for estimating the potential for environmental
 
releases from manufacturing and use industries as well as the potential
 
environmental burden, but it is difficult to obtain in the detail desired
 
since it is considered confidential business information for those
 
industries that manufacture 1,2-diphenylhydrazine. Release information is
 
similar to use information in that it is not obtained easily and can be used
 
to estimate environmental burdens and potentially exposed populations. A
 
Toxic Release Inventory will provide some of this information in the
 
future. Disposal information is useful for determining environmental burden
 
and potential concentrations where environmental exposures may be high.
 
Data on different disposal methods for 1,2-diphenylhydrazine are lacking.
 
According to the Emergency Planning and Community Right to Know Act of 1986
 
(EPCRTKA), (§313), (Pub. L. 99-499, Title III, §313), industries are
 
required to submit release information to the EPA. The Toxic Release
 
Inventory (TRI), which contains release information for 1987, became
 
available in May of 1989. This database will be updated yearly and should
 
provide a more reliable estimate of industrial production and emission.
 
Environmental Fate. Photolysis, photooxidation, and chemical oxidation
 
studies in air and water are lacking, as are persistence studies in soil and
 
groundwater. These kinds of studies are important since they address the
 
fundamental removal mechanisms available to 1,2-diphenylhydrazine in the
 
environment. In addition, removal mechanisms such as atmospheric
 
photooxidation may be several orders of magnitude faster than any other
 
removal mechanism; understanding these reactions is crucial to an
 
understanding of the fate of 1,2-diphenylhydrazine in the environment.
 
Biodegradation studies in water may not be important, even though they are
 
lacking, since 1,2-diphenylhydrazine oxidizes rapidly.
 
Bioavailability from Environmental Media. No studies were located
 
regarding the bioavailability of 1,2-diphenylhydrazine from environmental
 
media, but lack of these data does not necessarily indicate a lack of
 
bioavailability. As exposure to 1,2-diphenylhydrazine could occur at waste
 
sites by dermal contact with contaminated soil or by ingestion of
 
contaminated soil, it would be useful to know if dermal or oral absorption
 
of 1,2-diphenylhydrazine from environmental media could occur. Information
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available, but qualitative evidence indicates that 1,2-diphenylhydrazine in
 
diet or oil media is absorbed from the gastrointestinal tract (Section 2.3).
 
Food Chain Bioaccumulation. 1,2-Diphenylhydrazine reacts rapidly in
 
water to form azobenzene and other oxidation products (half-life in
 
wastewater is 60 minutes). Because of this and based upon the log
 




Exposure Levels in Environmental Media. Environmental monitoring data
 
are not available or are of questionable accuracy for water, soil, and air.
 
These data would be helpful in determining the ambient concentrations of 1,2­
diphenylhydrazine so that exposure estimates for the general population could
 




Exposure Levels in Humans. The database for exposure levels in humans is
 
very limited, and it is unclear if an exposed population exists given the
 
rapid disappearance of 1,2-diphenylhydrazine from the environment. While a
 
more complete database would be helpful in determining the current exposure
 
levels and thereby estimating the average daily dose associated with various
 
scenarios (e.g., living near a hazardous waste site, taking phenylbutazone), a
 




Exposure Registries. An exposure registry is not available. The
 
development of such a registry would be a useful reference tool in
 
assessing exposure levels and frequency. In addition, a registry would
 
allow an assessment of the variations in exposure concentrations from, for
 
example, geography, season, regulatory actions, presence of hazardous waste
 
landfills, or manufacturing and use facilities. These assessments, in
 
turn, would provide a better understanding of the need for research or data
 











The purpose of this chapter is to describe the analytical methods that
 
are available for detecting and/or measuring and monitoring
 
1,2-diphenylhydrazine in environmental media and in biological samples. The
 
intent is not to provide an exhaustive list of analytical methods that could
 
be used to detect and quantify 1,2-diphenylhydrazine. Rather, the intention
 
is to identify well-established methods that are used as the standard
 
methods of analysis. Many of the analytical methods used to detect
 
1,2-diphenylhydrazine in environmental samples are the methods approved by
 
federal agencies such as EPA and the National Institute for Occupational
 
Safety and Health (NIOSH). Other methods presented in this chapter are
 
those that are approved by a trade association such as the Association of
 
Official Analytical Chemists (AOAC) and the American Public Health
 
Association (APHA). Additionally, analytical methods are included that
 
refine previously used methods to obtain lower detection limits, and/or to
 




No adequate methods were located for the analysis of
 
1,2-diphenylhydrazine in biological materials. While thin-layer
 
chromatography methods have been published, it is not clear if these methods
 
would be capable of resolving 1,2-diphenylhydrazine from degradation
 
products that appear rapidly in a sample upon standing (Bolton and Griffiths
 
1978; Dutkiewicz and Szymanska 1973). These products (some unidentified)
 
are produced rapidly, and vary depending on the exact conditions (see
 
below). In addition, none of the metabolites identified (e.g., benzidine,
 
aniline) are suitable surrogates since they cannot be linked exclusively to
 
1,2-diphenylhydrazine exposure, but may result from exposure to other
 




Adequate analytical methods exist for the analysis of
 
1,2-diphenylhydrazine in environmental samples and are presented below.
 
However, adequate methods are not available for the sampling, sample
 
preservation, and sample preparation (extraction) of environmental media.
 
Neither EPA nor NIOSH have standard methods for analyzing
 
1,2-diphenylhydrazine in any medium; 1,2-diphenylhydrazine is no longer on
 
the Target Compound List (TCL) for the Contract Laboratory Program, but is
 
identified as a semi-volatile compound (EPA 1987a). Riggin and Howard
 
(1982) reported that 1,2-diphenylhydrazine at 100 µg/L in a municipal sewage 
effluent (after secondary treatment) had a time to 50% disappearance of 15 
minutes (it degraded completely within 1 hour), but the half-life was 
extended to 60 minutes when the wastewater was deaerated. Also, the authors 
stated that 1,2-diphenylhydrazine "... analysis in wastewater is virtually 
meaningless, since the DPH level determined cannot be directly related to 
the DPH in the sample at the time of collection." This limitation may apply 
to all environmental media, depending on the exact conditions used to 





methods for the analysis of 1,2-diphenylhydrazine will not necessarily yield
 




Extracting and concentrating the 1,2-diphenylhydrazine in an
 
environmental sample may give poor results. Riggin and Howard (1979)
 
reported that 1,2-diphenylhydrazine extraction from water was
 
"irreproducible" because of instability when the extract was concentrated.
 
An extraction efficiency of more than 50% was reported for chloroform
 
extraction at pH 7. If stored for longer than 1 day, however, the extract
 
contained less than 10% of the initial 1,2-diphenylhydrazine concentration.
 
At different pH values, 1,2-diphenylhydrazine degraded into different
 
products, not all of which were identifiable. This lack of clearly
 
identifiable degradation products makes identification of a degradation
 
product as a surrogate for 1,2-diphenylhydrazine difficult. Ahuja et al.
 
(1988) found that extraction of 1,2-diphenylhydrazine in water containing
 
THAM buffer (pH 9.2) showed only 0.9% loss over 30 minutes, although
 
chromatography was performed within 30 minutes of extraction. Although this
 
procedure was applied to pharmaceutical analysis, there is no apparent
 
reason to believe it will not work for environmental analysis.
 
In addition, Riggin and Howard (1982) reported that analytical
 
standards of 1,2-diphenylhydrazine prepared in benzene, methylene chloride,
 
methanol, triethyl amine, acetonitrile, or acetic acid decomposed
 
completely in 3 days or less. Matsui et al. (1983) reported that
 
1,2-diphenylhydrazine was oxidized to azobenzene in n-hexane solution at a
 
rate of about 5%/hr; flushing the n-hexane with nitrogen reduced the
 
conversion rate to about 4% in 2 hours. These authors also found that
 
nitrogen flushed standards were stable over a l-hour period, based on the
 
detector response factors during liquid chromatography. These limitations
 
should be considered when interpreting analytical results.
 
Riggin and Howard (1982) reported that 1,2-diphenylhydrazine
 
“. . . instantaneously decomposes to azobenzene in the GC injection port." The
 
authors further stated that:
 
"It is interesting to note that only one peak resulted from DPH
 
injection. Occasionally, it was found that a second, later
 
eluting peak was present . . . . but this was not always the case.
 




Because of this, GC, including GC/MS, does not appear to be an acceptable
 
analytical tool for the analysis of 1,2-diphenylhydrazine in any sample.
 
Riggin and Howard (1979, 1982), Matsui et al. (1983), Fabre et al.
 
(19841, and Ahuja et al. (1988) reported that High Performance Liquid
 
Chromatography (HPLC) with UV or electrochemical detection is capable of
 






have been used most often (Ahuja et al. 1988; Fabre et al. 1984; Riggin and
 
Howard 1979, 1982). Cyano-amino polar bonded phase columns also have been
 
used (Matsui et al. 1983). Using a reversed phase and UV detection, the
 
minimum amount detected (on column amounts) is approximately 6-7 ng and the
 
minimum amount quantifiable is less than 1 µg (Ahuja et al. 1988; Fabre
 
et al. 1984; Matsui et al. 1983).
 
In conclusion, HPLC is preferred over GC for analysis of
 




6.3 ADEQUACY OF THE DATABASE
 
Section 104(i)(5) of CERCIA, directs the Administrator of ATSDR (in
 
consultation with the Administrator of EPA and agencies and programs of the
 
Public Health Service) to assess whether adequate information on the health
 
effects of 1,2-diphenylhydrazine is available. Where adequate information
 
is not available, ATSDR, in conjunction with the NTP, is required to assure
 
the initiation of a program of research designed to determine the health
 




The following categories of possible data needs have been identified by
 
a joint team of scientists from ATSDR, NTP, and EPA. They are defined as
 
substance-specific informational needs that, if met would reduce or
 
eliminate the uncertainties of human health assessment. In the future, the
 
identified data needs will be evaluated and prioritized, and a
 
substance-specific research agenda will be proposed.
 
6.3.1 Identification of Data Needs
 
Methods for Determining Biomarkers of Exposure and Effect. No
 
biomarker that can be associated quantitatively with exposure to 1,2­
diphenylhydrazine has been identified (see Section 2.5). No adequate
 
methods are available for the analysis of 1,2-diphenylhydrazine in
 
biological materials. If this information were available, it would allow
 
both investigators and reviewers to assess the accuracy and uncertainty of
 
the methods used in toxicological studies. Furthermore, the ready
 
availability of tested analytical methods, including sample preservation,
 
would permit a standardized approach to the analysis of biological materials
 
to assist in measuring human exposure and monitoring effects in humans.
 
Adequate methods appear to be available for the analysis of 1,2­
diphenylhydrazine metabolites in biological materials. Metabolites include
 
azobenzene and aniline, both of which appear to be amenable to analysis by
 
standard methods. 1,2-Diphenylhydrazine and its metabolites, however, have
 








No biomarker that can be associated quantitatively with effect has been
 
identified (see Section 2.5). Thus, there are no analytical methods for the
 
determination of biomarkers of effect for 1,2-diphenylhydrazine.
 
Methods for Determining Parent Compound and Degradation Products in
 
Environmental Media. While analytical methods appear to be available for the
 
analysis of 1,2-diphenylhydrazine, no methods were found for the preservation
 
of 1,2-diphenylhydrazine in ambient air, water, or soil
 
samples. Such methods would allow the development and analysis of a
 
monitoring program designed to better assess the concentrations of
 
1,2-diphenylhydrazine in and around hazardous waste sites.
 
Methods for Determining Degradation Products in Environmental Media.
 
Adequate methods are available for the analysis of some
 
1,2-diphenylhydrazine degradation products in environmental media; however,
 
not all of the major degradation products have been identified. In
 
addition, the number and nature of degradation products appear to change
 
depending on conditions (e.g., pH). The development of adequate analytical
 
methods for identifying degradation products would allow a monitoring
 
program designed to assess the ambient concentrations of
 
1,2-diphenylhydrazine degradation products in environmental media to be
 
established; this would provide information concerning both human and
 
environmental exposure, since it would allow an estimation of the
 
concentration of 1,2-diphenylhydrazine in environmental media to be
 
established prior to degradation. The development of analytical methods,
 
however, must be subsequent to generalized environmental fate studies that
 
identify the degradation products. A standardized method could then be
 
developed using spike recoveries from different media to determine the
 










7. REGULATIONS AND ADVISORIES
 
National and state regulations and advisories pertinent to human
 
exposure to 1,2-diphenylhydrazine are summarized in Table 7-l. Guidance
 
from the World Health Organization (WHO) and the International Agency for
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Acute Exposure -- Exposure to a chemical for a duration of 14 days or less,
 
as specified in the Toxicological Profiles.
 
Adsorption Coefficient (Koc) -- The ratio of the amount of a chemical
 
adsorbed per unit weight of organic carbon in the soil or sediment to the
 
concentration of the chemical in solution at equilibrium.
 
Adsorption Ratio (Kd) -- The amount of a chemical adsorbed by a sediment or
 
soil (i.e., the solid phase) divided by the amount of chemical in the
 
solution phase, which is in equilibrium with the solid phase, at a fixed
 
solid/solution ratio. It is generally expressed in micrograms of chemical
 
sorbed per gram of soil or sediment.
 
Bioconcentration Factor (BCF) -- The quotient of the concentration of a
 
chemical in aquatic organisms at a specific time or during a discrete time
 
period of exposure divided by the concentration in the surrounding water at
 
the same time or during the same period.
 
Cancer Effect Level (CEL) -- The lowest dose of chemical in a study, or
 
group of studies, that produces significant increases in the incidence of
 




Carcinogen -- A chemical capable of inducing cancer.
 




Chronic Exposure -- Exposure to a chemical for 365 days or more, as
 
specified in the Toxicological Profiles.
 
Developmental Toxicity -- The occurrence of adverse effects on the
 
developing organism that may result from exposure to a chemical prior to
 
conception (either parent), during prenatal development, or postnatally to
 
the time of sexual maturation. Adverse developmental effects may be
 
detected at any point in the life span of the organism.
 
Embryotoxicity and Fetotoxicity -- Any toxic effect on the conceptus as a
 
result of prenatal exposure to a chemical; the distinguishing feature
 
between the two terms is the stage of development during which the insult
 
occurred. The terms, as used here, include malformations and variations,
 
altered growth, and in utero death.
 
EPA Health Advisory -- An estimate of acceptable drinking water levels for a
 
chemical substance based on health effects information. A health advisory is
 
not a legally enforceable federal standard, but serves as technical guidance
 






Immediately Dangerous to Life or Health (IDLH) -- The maximum environmental
 
concentration of a contaminant from which one could escape within 30 min
 
without any escape-impairing symptoms or irreversible health effects.
 
Intermediate Exposure -- Exposure to a chemical for a duration of 15-364 days
 
as specified in the Toxicological Profiles.
 
Immunologic Toxicity-- The occurrence of adverse effects on the immune
 




In Vitro -- Isolated from the living organism and artificially maintained,
 
as in a test tube.
 
In Vivo -- Occurring within the living organism.
 
Lethal Concentration(LO) (LC50) -- The lowest concentration of a chemical in 
air which has been reported to have caused death in humans or animals. 
Lethal Concentration(50) (LC50) -- A calculated concentration of a chemical in 
air to which exposure for a specific length of time is expected to cause death 
in 50% of a defined experimental animal population. 
Lethal Dose(LO) (LD LO) -- The lowest dose of a chemical introduced by a 
route other than inhalation that is expected to have caused death in humans 
or animals. 
Lethal Dose(50) (LD50) -- The dose of a chemical which has been calculated 
to cause death in 50% of a defined experimental animal population. 
Lethal Time(50) (LT50) -- A calculated period of time within which a 
specific concentration of a chemical is expected to cause death in 50% of a 
defined experimental animal population. 
Lowest-Observed-Adverse-Effect Level (LOAEL) -- The lowest dose of chemical in
 
a study, or group of studies, that produces statistically or biologically
 
significant increases in frequency or severity of adverse effects between the
 
exposed population and its appropriate control.
 
Malformations -- Permanent structural changes that may adversely affect
 
survival, development, or function.
 
Minimal Risk Level -- An estimate of daily human exposure to a chemical that
 
is likely to be without an appreciable risk of deleterious effects
 






Mutagen -- A substance that causes mutations. A mutation is a change in the
 




Neurotoxicity -- The occurrence of adverse effects on the nervous system
 
following exposure to chemical.
 
No-Observed-Adverse-Effect Level (NOAEL) -- The dose of chemical at which
 
there were no statistically or biologically significant increases in
 
frequency or severity of adverse effects seen between the exposed population
 
and its appropriate control. Effects may be produced at this dose, but they
 
are not considered to be adverse.
 
Octanol-Water Partition Coefficient (Kow) -- The equilibrium ratio of the 
concentrations of a chemical in n-octanol and water, in dilute solution. 
Permissible Exposure Limit (PEL) -- An allowable exposure level in
 
workplace air averaged over an g-hour shift.
 
ql* -- The upper-bound estimate of the low-dose slope of the dose-response
 
curve as determined by the multistage procedure. The qL* can be used to
 
calculate an estimate of carcinogenic potency, the incremental excess cancer
 
risk per unit of exposure (usually µg/L for water, mg/kg/day for food, and 
µg/m3 for air). 
Reference Dose (RfD) -- An estimate (with uncertainty spanning perhaps an
 
order of magnitude) of the daily exposure of the human population to a
 
potential hazard that is likely to be without risk of deleterious effects
 
during a lifetime. The RfD is operationally derived from the NOAEL (from
 
animal and human studies) by a consistent application of uncertainty factors
 
that reflect various types of data used to estimate RfDs and an additional
 
modifying factor, which is based on a professional judgment of the entire
 
database on the chemical. The RfDs are not applicable to nonthreshold
 
effects such as cancer.
 
Reportable Quantity (RQ) -- The quantity of a hazardous substance that is
 
considered reportable under CERCLA. Reportable quantities are (1) 1 lb or
 
greater or (2) for selected substances, an amount established by regulation
 
either under CERCLA or under Sect. 311 of the Clean Water Act. Quantities
 
are measured over a 24-hour period.
 
Reproductive Toxicity -- The occurrence of adverse effects on the
 
reproductive system that may result from exposure to a chemical. The
 
toxicity may be directed to the reproductive organs and/or the related
 
endocrine system. The manifestation of such toxicity may be noted as
 
alterations in sexual behavior, fertility, pregnancy outcomes, or
 








Short-Term Exposure Limit (STEL) -- The maximum concentration to which
 
workers can be exposed for up to 15 min continually. No more than four
 
excursions are allowed per day, and there must be at least 60 min between
 
exposure periods. The daily TLV-TWA may not be exceeded.
 
Target Organ Toxicity -- This term covers a broad range of adverse effects
 
on target organs or physiological systems (e.g., renal, cardiovascular)
 
extending from those arising through a single limited exposure to those
 
assumed over a lifetime of exposure to a chemical.
 
Teratogen -- A chemical that causes structural defects that affect the
 
development of an organism.
 
Threshold Limit Value (TLV) -- A concentration of a substance to which most
 
workers can be exposed without adverse effect. The TLV may be expressed as
 
a TWA, as a STEL, or as a CL.
 
Time-Weighted Average (TWA) -- An allowable exposure concentration averaged
 
over a normal 8-hour workday or 40-hour workweek.
 
Toxic Dose (TD50) -- A calculated dose of a chemical, introduced by a route 
other than inhalation, which is expected to cause a specific toxic effect in 
50% of a defined experimental animal population. 
Uncertainty Factor (UF) -- A factor used in operationally deriving the RfD
 
from experimental data. UFs are intended to account for (1) the variation
 
in sensitivity among the members of the human population, (2) the
 
uncertainty in extrapolating animal data to the case of human, (3) the
 
uncertainty in extrapolating from data obtained in a study that is of less
 
than lifetime exposure, and (4) the uncertainty in using LOAEL data rather
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